ArcticZymes Technologies today reported financial results for the fourth quarter and full year 2025,reflecting accelerating sales growth, improved operating leverage and continued penetration in its core business segments. Following a return to growth in 2025, the Company enters 2026 with strengthened commercial momentum and a robust balance sheet.
Q4 2025 Highlights
- Total revenue: NOK 34.7 million (Q4 2024: NOK 26.4 million), +31% year-on-year
- Sales revenue: NOK 34.1 million (Q4 2024: NOK 24.5 million), +39% year-on-year
- Constant currency sales: NOK 36.3 million, +46%
- EBITDA: NOK 8.3 million (Q4 2024: NOK 2.5 million)
- EBITDA margin: 24% (Q4 2024: 11%)
Q4 marked a strong close to the year, driven by continued penetration in Biomanufacturing and robust performance in Molecular Tools.
Full Year 2025 Highlights:
- Total revenue: NOK 118.2 million (2024: NOK 108.1 million), +9%
- Sales revenue: NOK 112.6 million (2024: NOK 104.4 million), +8%
- Constant currency sales: NOK 114.9 million, +11%
- EBITDA: NOK 12.0 million (2024: NOK 5.1 million)
- Profit before tax: NOK 12.2 million (2024: NOK 10.6 million)
The Company returned to growth in 2025, supported by commercial execution, improved product mix and disciplined cost management.
Financial Position
- Net cash flow: NOK 5.4 million in Q4; NOK 16.8 million year-to-date (2024: NOK –9.9 million)
- Cash and cash equivalents: NOK 187.8 million
- Additional liquid interest-bearing funds: NOK 76.9 million
- No interest-bearing debt
ArcticZymes maintains a strong balance sheet, providing financial flexibility to support continued organic expansion, targeted portfolio investments and disciplined evaluation of strategic opportunities.
Business Segment Performance
Biomanufacturing
- Q4 revenue: NOK 15.2 million (+25% YoY), representing 45% of total sales
- Full-year revenue growth: +23%
- GMP-grade product sales increased approximately 106% YoY in Q4
- SAN portfolio achieved its second-highest annual sales level (after 2022)
Growth was supported by increasing adoption among CDMO customers and progression of clients into later-stage development programs.
Molecular Tools
- Q4 revenue: NOK 18.9 million (+55% YoY), representing 55% of total sales
- Full-year revenue declined 6% versus 2024
Q4 performance reflects increased activity from a key account combined with broader customer growth, partially offsetting reduced purchasing earlier in the year.
CEO Commentary
“Q4 marked a strong finish to 2025, with 39% sales growth and a significant improvement in EBITDA compared with last year,” said Michael Akoh, CEO of ArcticZymes Technologies ASA. “We returned to growth in 2025 and enter 2026 with solid commercial momentum, improving profitability and a strong financial position to support further expansion.”
Outlook
ArcticZymes remains focused on driving sustainable growth through:
- Continued scaling of Biomanufacturing, with increased GMP-grade penetration
- Expansion of CDMO partnerships to build long-term revenue visibility
- Broader enzyme application development, including metagenomics
- Further build-out of the RNA enzyme portfolio, including the launch of ET-N1
With a strengthened commercial platform, expanding application footprint and a solid balance sheet, the Company is well positioned for continued growth in 2026 and beyond.
